Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Recruiting 3

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Classical hematology 2Other hematologic neoplasm 1Myeloid 1Lymphoid 1CNS 1

Conditions

Breast Neoplasms 1035Neoplasms 813Carcinoma, Non-Small-Cell Lung 796Prostatic Neoplasms 617Colorectal Neoplasms 533Lung Neoplasms 478Neoplasm Metastasis 434Multiple Myeloma 394Leukemia, Myeloid, Acute 380Ovarian Neoplasms 333Pancreatic Neoplasms 316Melanoma 293Squamous Cell Carcinoma of Head and Neck 266Recurrence 260Carcinoma, Hepatocellular 248Glioblastoma 237Brain Neoplasms 236Triple Negative Breast Neoplasms 213Head and Neck Neoplasms 210Carcinoma, Renal Cell 207Precursor Cell Lymphoblastic Leukemia-Lymphoma 203Lymphoma 198Stomach Neoplasms 197Endometrial Neoplasms 190Uterine Cervical Neoplasms 182Lymphoma, Non-Hodgkin 182Sarcoma 180Glioma 179Lymphoma, Large B-Cell, Diffuse 166Hematologic Neoplasms 162

Interventions

thymoglobulin 2fludarabine 2Rituximab 2Cyclophosphamide 2luspatercept 1Tacrolimus 1Mycophenolic Acid 1Melphalan 1Levetiracetam 1Dexamethasone 1Busulfan 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × beta-Thalassemia × 90 days × Clear all
NCT05736419 2026-06-03

A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
24 enrolled
Classical hematology

Anemia, Sickle Cell, Thalassemia, beta-Thalassemia

NCT04064060 2026-05-28

A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

Celgene

Phase 3 Recruiting
665 enrolled
Myeloid

Myelodysplastic Syndromes, Myeloproliferative Disorders, beta-Thalassemia

NCT05735717 2026-04-06

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

Masonic Cancer Center, University of Minnesota

Phase 2 Recruiting
70 enrolled
CNSClassical hematologyLymphoidOther hematologic neoplasm

Chromosome 7, monosomy, Anemia, Refractory, with Excess of Blasts, Chromosome Aberrations, Influenza, Human, Neurofibromatosis 1, Leukemia, Myeloid, Acute, beta-Thalassemia, Neoplasm, Residual, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myelomonocytic, Juvenile

Data powered by HemOnc (CC BY 4.0) Colophon âš¡